{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037446","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.180781+00:00","generated_at":"2026-06-08T13:22:42.468656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cumberland Q3 2023: net loss $1.0M, revenue $10.1M, YTD adj. EPS $0.29","bullets":["Net loss of $1.0M; adjusted earnings $260K ($0.02/share); YTD net income $15K, adj. EPS $0.29.","Product revenue $10.1M (Kristalose $3.9M, Vibativ $2.8M, Sancuso $1.9M, Caldolor $1.2M).","New $25M revolving credit facility with Pinnacle Bank; $12.9M drawn at quarter-end.","Sancuso acquisition transition completed; FDA approved new mfg plant; supplies underway Q4 2023.","NOPAIN Act may provide separate Medicare reimbursement for Caldolor from 2025; ifetroban Phase II trials ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037446","json":"https://secwatch.observer/filing/0001628280-23-037446.json","markdown":"https://secwatch.observer/filing/0001628280-23-037446.md","text":"https://secwatch.observer/filing/0001628280-23-037446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/0001628280-23-037446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/cpix-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:22:42.468656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ece52178ebf6917b6bfb101175a19a1a49e1d459","claim":"CUMBERLAND PHARMACEUTICALS INC reported financial results for the three and nine months ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Cumberland Pharmaceuticals Inc. (the \"Company\") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/0001628280-23-037446-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}